Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy.
Plasma testosterone, androstenedione, oestradiol-17beta, follicle stimulating hormone (FSH) and luteinizing hormone (LH) were not significantly different in patients with prostatic cancer, with benign prostatic hyperplasia or in patients without prostatic disease. Plasma prolactin concentrations were significantly lower in the patients with benign disease than those with prostatic carcinoma. Endocrine therapy in the form of stilboestrol administration significantly decreased plasma levels of testosterone, oestradiol-17beta, FSH and LH within 7 days of the treatment. After 7 days therapy prolactin levels increased significantly in all patients studied. Changes in growth hormone concentrations were more varied in response to stilboestrol, being elevated in several patients and remaining unchanged in others. Treatment of a few prostatic carcinoma patients who were receiving stilboestrol therapy with CB154, an inhibitor of prolactin secretion, brought an immediate decrease in prolactin  levels which was was sustained. Plasma testosterone, androstenedione and growth hormone were unchanged in these patients but a significant decrease in plasma oestradiol-17beta was noted in two patients during CB154 administration.
D000368:Aged; D000735:Androstenedione / Q000097:blood; D002277:Carcinoma / Q000188:drug therapy; D004958:Estradiol / Q000097:blood; D005640:Follicle Stimulating Hormone / Q000097:blood*; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy; D013256:Steroids / Q000097:blood*; D013739:Testosterone / Q000097:blood
D013256:Steroids; D013739:Testosterone; D000735:Androstenedione; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone